Sunday
Matthias Schwab - The clinical relevance of drug-drug and drug-herb interactions
Rashmi Shah - The evolution of regulatory guidance on drug-drug interactions
Geoff Tucker - The prediction of metabolic drug-drug interations from in vitro data
Colin Baigent - Understanding the uses and limitations of RCTs
Ragnar Lofstedt - Risk communication and health: relevance to therapeutics
John Urquhart - Concordance, compliance and adherence
Joeline Jochemsen - Drug-drug interactions as an issue in drug development
Munir Pirmohamed - Anticipating adverse drug reactions
David Back - Anticipating adverse drug interactions
Jeff Aronson - Balanced prescribing and the information that we need to achieve it
John Cockroft - European clinical research - over regulated and under supported?
Stephen Rees - High throughput screening approaches to support drug discovery
Philippe Beaune - Pharmacogenetics and drug development
Mark Sculpher - How can we measure the cost-effectiveness of medical interventions?
Martin Duerden - Formularies: why do we need them and how do you make one?
Simon Maxwell - Ethical issues in clinical pharmacology
Igor Francetic - Pharmacovigilance and rational drug prescribing in Eastern European countries
Sandor Kerpel-Fronius - Education of clinical pharmacology in Eastern Europe: quo vadis?
Violeta Stanimirovic - Regulatory environment in the non-EU European countries
Colin Garner - The use of human phase 0 microdose studies in exploratory clinical development
David Montgomery - Debate: The pharmaceutical industry should have a greater role in providing patients with drug information (For)
Des Spence - Debate: The pharmaceutical industry should have a greater role in providing patients with drug information (Against)
|
Congress of the European Association for Clinical Pharmacology and TherapeuticsEdinburgh, Scotland 12 - 15th July 2009